Pfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
Prelude has provided a follow on investment to support the security software provider.
"As a company that is immersed in the connected world and sees the latest use cases being deployed by our customers all over the world, we are acutely aware of how important it is to ensure complete trust in the devices and data being used. Our KSaaS cloud service and KeyScaler platform has already been recognised as the ‘Rising Azure Technology’ in Microsoft’s Partner of The Year Awards and by analysts who have identified Device Authority as the technological leader in its field. We are delighted that Prelude has joined our recent financing with Ten Eleven Ventures to also support our ongoing growth journey as we continue to advance our solution and grow our presence in North America."
The financing will support the commercial rollout of synthetic affinity reagents and team expansion.
"Securing funding for a novel reagents company in today's investment landscape demonstrates clear confidence in MIP Discovery's technology and renewed commercial strategy. Our proprietary modeling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space."
The oversubscribed round was backed by existing and new strategic investors to fund US expansion and generative AI development.
"This successful financial raise allows us to increase the size of our in-house development team by recruiting new talent who will focus on building Proteus’s generative AI. This will further help our clients optimise their project performance. In addition, the raise will support our growth into Australia and our planned entry into the United States later in 2024."
Verisk and BGF have backed cyber risk management provider KYND in its latest funding round.
"KYND has developed an industry-leading platform that provides actionable insights on cyber risk posture. The business has demonstrated impressive growth and this new investment demonstrates our belief in the long-term potential of the company as it continues to scale."